(in which tissue samples are removed for testing). Even then, results do not always correlate with the symptoms, making it hard to assess the severity of the condition. Fortunately, there have been a number of promising scientific developments in recent years. “There’s been a surge in awareness of the condition,” says Krina Zondervan of Oxford University. More patient data have helped, too. Australia, Denmark, France and Spain have launched action plans to improve clinical care or boosted funding for the condition. After decades in the dark, researchers are rapidly moving towards a clearer understanding of the forms endometriosis takes, less invasive ways of diagnosing the condition and a variety of possible treatments. Dr Zondervan’s work helped trigger this transformation. In 2023 she and her colleagues published the results of what was then the largest-ever study of endometriosis. It compared the genetic data of 60,000 women who had the condition with those of more than 700,000 without it. Among the genetic markers common in patients were a number linked to other painful and inflammatory conditions. This suggests potential avenues for treatment. The following year Dr Zondervan and her team published a detailed map of the types of cells in the uterine lining, including those embedded deep in tissue layers. This allowed them to describe how cells communicate throughout the menstrual cycle, and to pinpoint the cell types most likely to be affected by the genetic markers associated with endometriosis. More progress was made in April when a team led by Dora Koller, a researcher at the Sant Pau Research Institute in Spain, published the results of an even larger genetic study. It covered 1.4m women, including more than 105,000 with endometriosis. Their results linked specific genes to immune- system responses and hormonal processes characteristic of endometriosis, as well as identifying a genetic connection with chronic fatigue, a symptom that doctors frequently dismiss. Such work will help scientists identify genetic risk factors for endometriosis. Dr Koller, who has endometriosis herself, says her team’s results support the idea that the disease affects the whole body, rather than being confined to a woman’s pelvis. She says their study could guide new drug development and

give researchers clues about whether existing treatments that work for other painful diseases could be used for endometriosis, too. Research efforts on quicker and less invasive means of diagnosing the disease have also ramped up. Katherine Burns of the University of Cincinnati, who has also experienced endometriosis, has spent time studying white blood cells in the menstrual fluid of women with the disease. She has found they are distinctive in two ways: the cell nuclei are smaller, and they have more lobes than their healthy equivalents. Dr Burns is now using that information to develop ways to diagnose endometriosis without the need for surgery. Another diagnostic approach is to rely on molecular biomarkers such as proteins and microRNAs (short molecules that regulate gene expression) that feature in the body’s inflammatory and immune response to endometriosis. In March scientists from various organisations, including HerAnova Lifesciences, a Boston-based firm, reported that detecting several of these biomarkers could be used to diagnose endometriosis. In 61.5% of these cases, vaginal ultrasounds and imaging had missed signs of the disease. An even less invasive way to diagnose and monitor endometriosis was described in the Lancet Obstetrics and Gynaecology in April. Researchers at Oxford found a new imaging agent (a dye or contrast that is injected into the body to see microscopic biological processes) that was well tolerated by patients with superficial peritoneal endometriosis, the most prevalent early- stage form of the disease. 99mTc-maraciclatide, as the agent is known, attaches to cell receptors that signal inflammatory conditions, causing it to accumulate in areas where there is inflammation. The hot spots can then be seen with imaging tools. Maraciclatide, which is being developed by Serac Healthcare, a pharmaceutical company based in London, hopes to go through phase-3 trials (when compounds are tested at scale in humans) and validation in the near future. More avenues for treating endometriosis are also opening up. In March, Gesynta Pharma, a Swedish pharma company, announced that it had begun its phase-2 clinical trial of Vipoglanstat. Instead of interacting with hormones, as existing treatments do, the drug blocks an enzyme that is

needed to make a pain-related chemical in the body. In doing so it reduces pain and inflammation, making life more bearable. A non-hormonal treatment developed by EndoCyclic Therapeutics, a biopharmaceuticals firm, was cleared by America’s drug regulator for phase-1 human trials in March. Called ENDO-205, it aims to go one better: clearing lesions and reducing the rate at which they recur. More funding may well lead to more progress. Much of the work so far has been done “on a shoestring”, says Dr Zondervan. America’s National Institutes of Health allocates less than 0.1% of its budget to endometriosis— far less than that for much rarer conditions (Crohn’s disease, for example, receives about 15 times more money per patient). A programme launched in 2024 under President Joe Biden to fund women’s health research, including endometriosis, was cut this year. With more cash researchers could conduct trials on women from across the world, to understand how varied the effects of endometriosis are. They could also generate richer data to help distinguish between the disease’s many forms and investigate the different types of lesions involved. Such advances could, then, drive the development of targeted therapies that might bring relief to millions. ■ This article was downloaded by zlibrary from https://www.economist.com/science-and-technology/2026/11/09/scientists-are-at-last- starting-to-understand-endometriosis

Science & technology | Mental block The blood-brain barrier may contribute to cognitive function Studies in mice suggest it is more sophisticated than once thought Nov 12th 2026 AS THE COMMAND centre of the human body, the brain requires the best protection biology can supply. The hard, bony casing of the skull helps to shield the organ from threats outside the body. But dangers lie within, too. Blood can contain toxins and pathogens which would wreak havoc in the brain’s delicate environment. Keeping such vandals out is the job of the blood-brain barrier, a tightly packed network of cells coating the interior surfaces of blood vessels leading to the brain. In a new study, published in Cell on November 11th, a team led by Andrew Yang, a neuroscientist at the Gladstone Institute of Neurological Disease in San Francisco, has shown that the blood-brain barrier is surprisingly sophisticated. By cataloguing the proteins that were allowed through the

barrier in mice, the researchers found that it plays a far more active role in brain health than previously thought. The barrier both protects the organ and keeps it supplied with beneficial proteins. The team believe their results may suggest a new approach to treating Alzheimer’s disease. The blood-brain barrier is more like a bouncer than a brick wall. Its cells keep the harmful stuff out while letting in a select few essential molecules found in blood, such as oxygen and glucose, which fuel neural processes. It also ensures that conditions inside the brain are optimal by expelling any unwanted molecular by-products back into the bloodstream. By controlling what gets in and out, the barrier keeps the brain’s chemical environment stable and its neurons firing properly. But which molecules are on the brain’s guest list, and why, have so far remained unclear. To answer this question, Dr Yang and his team tagged the proteins in mouse blood with small chemicals that would be invisible to mouse biology. By subsequently extracting brain tissue and identifying any tags within it, the researchers could see which proteins had ended up where. “What we started seeing is that there was an unexpected breadth and diversity of proteins in the blood that made their way into the brain,” says Dr Yang. Of the 861 tagged proteins, 92 reached the brain’s tissue. Further contrary to their expectations, such physical features as size or electric charge did not affect which proteins made it through. Most had also been produced in organs far from the brain. The surprises did not stop there. “We thought [the proteins] would cross and then just get dumped into the brain,” says Dr Yang. Instead, his team found that the proteins appeared to target specific cells. One protein, known as apolipoprotein A1 (APOA1), began accumulating in cells called astrocytes which perform a variety of supporting jobs around the brain. In cells kept alive outside the mice’s bodies, the researchers found that APOA1 helped the astrocytes deliver molecules of cholesterol to the neurons, which use the stuff to build and maintain connections between one another. APOA1, which is produced primarily in the liver, thus appeared to support a crucial neural process.

APOA1 also engaged with a gene whose reduced function has been linked to the risk of Alzheimer’s disease. When the team applied their protein-tagging technique to mice with an early-stage Alzheimer’s-like condition, they found that less APOA1 got through the blood-brain barrier. Conversely, when the researchers engineered the mice’s livers to produce extra APOA1, they saw a corresponding rise in the protein’s levels in the brain. The number of neuronal connections in treated mice increased, and their performance on movement and memory tests improved. “If validated in humans, this work could open an entirely new therapeutic field,” says Egle Solito, an immunobiologist at Queen Mary University of London. The blood-brain barrier’s connection to Alzheimer’s is not new. It has long been known that a weakened barrier, accompanied by a leak of harmful proteins into the brain, is an early sign of the disease. But Dr Yang’s findings suggest that it is not only the barrier’s erosion that may be harmful but also its failure, while still intact, to supply protective proteins to the brain. He reckons many more surprises await. ■ This article was downloaded by zlibrary from https://www.economist.com/science-and-technology/2026/11/11/the-blood-brain- barrier-may-contribute-to-cognitive-function

Science & technology | Run of the Yang-Mills AI has proved that a theory underpinning fundamental physics is trustworthy The key insights appear to have come from human physicists Nov 12th 2026 ON OCTOBER 26TH OpenAI, an artificial-intelligence lab, announced that one of its unreleased models had taken a significant step towards solving one of the open Millennium Prize problems, some of the biggest challenges in maths. Known as the Yang-Mills existence and mass gap problem, it is closely related to models of the subatomic world routinely used by quantum physicists. Those eager to see the proof have had to wait while a committee of five external physicists assessed its validity. On November 10th they declared themselves satisfied. The problem concerns a set of equations, known as Yang-Mills theory, which physicists have long used to describe the working of three of the four known fundamental forces: electromagnetism and the strong and weak